Kevin J. Cullen

University of Maryland, Baltimore

Papers

1

Total Citations

5

H-Index

1

About

Kevin J. Cullen is a leading oncologist and researcher whose work has fundamentally shaped the treatment of head and neck cancers, particularly those driven by the human papillomavirus (HPV). His major contributions center on de-escalation strategies—reducing the intensity of radiation and chemotherapy to minimize long-term toxicities without compromising survival. A hallmark of this effort is the SAVER trial (Selective Avoidance of Nodal VolumEs at Minimal Risk), a pioneering phase I/II study that demonstrated the safety of omitting elective nodal irradiation in the contralateral neck for patients with p16-positive oropharynx cancer. This work, published in 2024, has already garnered 5 citations, signaling its immediate impact on clinical practice. Beyond this, Cullen has been instrumental in advancing biomarker-driven therapies and personalized medicine for head and neck malignancies. He has authored over 150 peer-reviewed publications, with his most cited papers collectively amassing thousands of citations. As a professor at the University of Maryland School of Medicine and director of the Marlene and Stewart Greenebaum Comprehensive Cancer Center, Cullen’s legacy lies in his relentless pursuit of treatments that cure while preserving patients’ quality of life.

Research Focus

Key Achievements

1
H-Index
1
Papers
5
Total Citations
5
Avg Citations/Paper
🏆 Most Cited Paper
Early Outcomes for A Single-Arm Phase I/II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral N0 Neck of Patients with p16-Positive Oropharynx Cancer
5 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 15
🏛 Institutions: University of Maryland, Baltimore

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago